GSK has no immediate plans to spin off Pfizer joint ventureGlaxoSmithKline has made no plans to spin off or float its consumer healthcare joint venture with Pfizer, according Share XGSK has no immediate plans to spin off Pfizer joint venturehttps://pharmaphorum.com/news/gsk-spin-off-pfizer-joint-venture/
ViiV’s two-drug HIV therapy Dovato gets Japanese approvalOne of ViiV Healthcare’s two-drug HIV therapies – Dovato – has been approved in Japan, providing a new Share XViiV’s two-drug HIV therapy Dovato gets Japanese approvalhttps://pharmaphorum.com/news/viivs-two-drug-hiv-therapy-dovato-gets-japanese-approval/
GSK’s CEO Walmsley aiming for six new approvals in 2020GlaxoSmithKline’s CEO Emma Walmsley has said the company hopes to get at least six new drug approvals in Share XGSK’s CEO Walmsley aiming for six new approvals in 2020https://pharmaphorum.com/news/gsks-ceo-walmsley-aiming-for-six-new-approvals-in-2020/
ViiV files first-in-class HIV drug in EuropeViiV Healthcare has filed its new HIV drug fostemsavir for approval in Europe, a few weeks after the Share XViiV files first-in-class HIV drug in Europehttps://pharmaphorum.com/news/viiv-files-first-in-class-hiv-drug-in-europe/
GSK completes travel vaccine offload as revamp continuesGlaxoSmithKline’s last act of 2019 was the completion of its near-€1 billion deal to divest two vaccines to Share XGSK completes travel vaccine offload as revamp continueshttps://pharmaphorum.com/news/gsk-completes-travel-vaccine-offload-as-revamp-continues/
Novartis top of pile in European pharma in 2020, say Jefferies analystsJefferies’ team of analysts have recently been touting Roche as their favourite big European pharma – but going Share XNovartis top of pile in European pharma in 2020, say Jefferies analystshttps://pharmaphorum.com/news/novartis-top-of-pile-in-european-pharma-say-jefferies-analysts/
GSK files multiple myeloma drug with FDA after phase 2 successGSK has filed for FDA approval of its potential first-in-class multiple myeloma drug belantamab mafodotin for relapsed/refractory multiple Share XGSK files multiple myeloma drug with FDA after phase 2 successhttps://pharmaphorum.com/news/gsk-files-multiple-myeloma-drug-with-fda-after-phase-2-success/
GSK leanest with R&D spend in big pharma – but gets bang for its buckGlaxoSmithKline’s CEO Emma Walmsley has made great play of her company’s new approach to R&D under the leadership Share XGSK leanest with R&D spend in big pharma – but gets bang for its buckhttps://pharmaphorum.com/news/gsk-is-meanest-with-rd-spend-in-big-pharma/
Chasing Mylan, Hikma tries again with rejected generic Advair in USUK-listed Hikma Pharma has filed a response to the FDA that it hopes will clear the way for Share XChasing Mylan, Hikma tries again with rejected generic Advair in UShttps://pharmaphorum.com/news/chasing-mylan-hikma-tries-again-with-rejected-generic-advair-in-us/
